tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Indaptus Therapeutics: Promising Clinical Developments and Strategic Advances Justify Buy Rating

Indaptus Therapeutics: Promising Clinical Developments and Strategic Advances Justify Buy Rating

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Indaptus Therapeutics (INDPResearch Report), with a price target of $2.00.

Elevate Your Investing Strategy:

Jason McCarthy has given his Buy rating due to a combination of factors related to Indaptus Therapeutics’ promising clinical developments and strategic approach. The company has made significant progress with its Decoy20 platform, which is designed to stimulate the immune system against advanced solid tumors. The initiation of the P1b/2 trial combining Decoy20 with the anti-PD1 therapy, tislelizumab, marks a critical step forward, as early indications suggest that the combination is safe and well-tolerated.
Moreover, the trial’s design, which includes sequential patient enrollment and monitoring, ensures a thorough evaluation of safety and efficacy. The positive safety profile observed in previous studies, along with the potential to prime the immune system for anti-tumor activity, enhances the platform’s attractiveness. McCarthy’s valuation model, which considers multiple cancer indications and applies risk adjustments, supports a favorable price target, reinforcing the Buy rating.

INDP’s price has also changed dramatically for the past six months – from $1.000 to $0.340, which is a -66.00% drop .

Disclaimer & DisclosureReport an Issue

1